Home › Calculator › AURX Dividend Calculator 2026
AURX Dividend DRIP Calculator 2026
235.29% YieldHealthcareNuo Therapeutics, Inc. · OTC
Price: $0.85 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When AURX pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your AURX snowball 📈
$10,000 in AURX → $1795.81M in 10 years · $105,017,876.53/month
About Nuo Therapeutics, Inc. (AURX) — Dividend Analysis 2026
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Compare AURX with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full AURX DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open AURX position with:
🌍 AURX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold AURX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 235.29% | 232.49% | $23,529 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 200.00% | 197.20% | $20,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 188.23% | 185.43% | $18,823 / yr |
| 🇬🇧 UK ISA | 0% | 235.29% | 232.49% | $23,529 / yr |
| 🇬🇧 UK Taxable | 8.75% | 214.70% | 211.90% | $21,470 / yr |
| 🇨🇦 TFSA | 0% | 235.29% | 232.49% | $23,529 / yr |
| 🇨🇦 CA Taxable | 25% | 176.47% | 173.67% | $17,647 / yr |
| 🇦🇺 Super (pension) | 15% | 200.00% | 197.20% | $20,000 / yr |
| 🇦🇺 AU Taxable | 30% | 164.70% | 161.90% | $16,470 / yr |
| 🇩🇪 DE Taxable | 26.375% | 173.23% | 170.43% | $17,323 / yr |
| 🇫🇷 FR Taxable | 30% | 164.70% | 161.90% | $16,470 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 AURX Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 AURX Dividend Payment Schedule
AURX pays quarterly — 4 times per year. Next ex-div: TBD.
📊 AURX vs Healthcare Benchmarks
How AURX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for AURX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ AURX Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2026-08-28 | 7,984 | $1.09 | $8.7K | ||
| Buy | 2026-08-27 | 789 | $1.07 | $844.00 | ||
| A-Award | 2026-08-28 | 7,984 | $1.09 | $8.7K | ||
| A-Award | 2026-08-27 | 789 | $1.07 | $844.00 | ||
| A-Award | 2026-06-29 | 65,000 | $1.01 | $65.7K | ||
| M-Exempt | 2026-06-30 | 162,500 | $1.00 | $162.5K | ||
| F-InKind | 2026-06-30 | 160,892 | $1.01 | $162.5K | ||
| A-Award | 2026-06-29 | 125,000 | $1.01 | $126.3K | ||
| M-Exempt | 2026-06-30 | 162,500 | $1.00 | $162.5K | ||
| M-Exempt | 2026-06-30 | 40,000 | $1.00 | $40.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where AURX earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the AURX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Nuo Therapeutics, Inc. (AURX) is currently trading at $0.85, 78% below its 52-week high. The current dividend yield is 235.29% based on an annual payout of $2.00 per share.
AURX (Nuo Therapeutics, Inc.) — 235.29% Dividend Yield Analysis
Nuo Therapeutics, Inc. (AURX) is a healthcare stock currently trading at $0.85 with a dividend yield of 235.29%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (235.29%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.